Nuvation Bio Reports Q1 2026 Earnings with Revenue Growth and Patient Data
Nuvation Bio (NUVB) reported Q1 2026 earnings with total revenue of $83.2 million, driven by growth in Iptrozy net U.S. product revenue. The company noted an increase in first-line patient starts and improved median duration of response in TKI-naive patients, signaling positive trends in its drug's performance.
Tickers: $NUVB
Topics: Clinical Trial Results Patient Outcomes Product Performance Revenue Growth